More Articles Back to Article
Draft guidance by NICE backs 3 COVID-19 drugs
A new draft guidance released by the National Institute for Health and Care Excellence recommended COVID-19 treatments tocilizumab by Roche and Eli Lilly and Co.'s baricitinib in hospital settings and Pfizer's tirmatrelvir plus ritonavir in non-hospital settings. The organization withheld its recommendation for two drugs that the appraisal committee considered not cost-effective and three which did not conclusively show their effectiveness against the Omicron variant. PMLive (UK) (11/16)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!